Clinical Review on the Management of Metastatic Renal Cell Carcinoma von Tran, Jennifer, Ornstein, Moshe C

Volltext

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target von Koshkin, Vadim S, Garcia, Jorge A, Reynolds, Jordan, Elson, Paul, Magi-Galluzzi, Cristina, McKenney, Jesse K, Isse, Kumiko, Bishop, Evan, Saunders, Laura R, Balyimez, Aysegul, Rashid, Summya, Hu, Ming, Stephenson, Andrew J, Fergany, Amr F, Lee, Byron H, Haber, Georges-Pascal, Dowlati, Afshin, Gilligan, Timothy, Ornstein, Moshe C, Rini, Brian I, Abazeed, Mohamed E, Mian, Omar Y, Grivas, Petros

Volltext

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma von Koshkin, Vadim S, Barata, Pedro C, Zhang, Tian, George, Daniel J, Atkins, Michael B, Kelly, William J, Vogelzang, Nicholas J, Pal, Sumanta K, Hsu, JoAnn, Appleman, Leonard J, Ornstein, Moshe C, Gilligan, Timothy, Grivas, Petros, Garcia, Jorge A, Rini, Brian I

Volltext

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook von Gopalakrishnan, Dharmesh, Koshkin, Vadim S, Ornstein, Moshe C, Papatsoris, Athanasios, Grivas, Petros

Volltext

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma von Dawsey, Scott J., Ornstein, Moshe C.

Volltext

Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature von Dawsey, Scott J., Campbell, Steven C., Ornstein, Moshe C.

Volltext

Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis von Tzeng, Alice, Tzeng, Tony H, Ornstein, Moshe C

Volltext

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab von Zahoor, Haris, Barata, Pedro C, Jia, Xuefei, Martin, Allison, Allman, Kimberly D, Wood, Laura S, Gilligan, Timothy D, Grivas, Petros, Ornstein, Moshe C, Garcia, Jorge A, Rini, Brian I

Volltext

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro von Campbell, Steven C., Ornstein, Moshe C., Rathi, Nityam

Volltext

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab von Brown, Landon C., Desai, Kunal, Wei, Wei, Kinsey, Emily N., Kao, Chester, George, Daniel J., Rini, Brian I., Ornstein, Moshe C., Zhang, Tian

Volltext

Targeting HIF-2 Alpha in Renal Cell Carcinoma von Ahmed, Ramsha, Ornstein, Moshe C.

Volltext

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) von Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, Mcdermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Einstein, David, Catalano, Paul J, Hammers, Hans, Regan, Meredith M

Volltext

More is better: Combination therapies for myelodysplastic syndromes von Ornstein, Moshe C., MD, MA, Mukherjee, Sudipto, MD, PhD, MPH, Sekeres, Mikkael A., MD, MS

Volltext

The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma von Nizam, Amanda, Schindelheim, Jonah A., Ornstein, Moshe C.

Volltext

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy von Ornstein, Moshe C, Wood, Laura S, Hobbs, Brian P, Allman, Kimberly D, Martin, Allison, Bevan, Michael, Gilligan, Timothy D, Garcia, Jorge A, Rini, Brian I

Volltext

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma von Brown, Landon C, Zhu, Jason, Desai, Kunal, Kinsey, Emily, Kao, Chester, Lee, Yong Hee, Pabla, Sarabjot, Labriola, Matthew K, Tran, Jennifer, Dragnev, Konstantin H, Tafe, Laura J, Dayyani, Farshid, Gupta, Rajan T, McCall, Shannon, George, Daniel J, Glenn, Sean T, Nesline, Mary K, George, Saby, Zibelman, Matthew, Morrison, Carl, Ornstein, Moshe C, Zhang, Tian

Volltext

The Immunotherapy Landscape in Renal Cell Carcinoma von Brown, Landon C., Desai, Kunal, Zhang, Tian, Ornstein, Moshe C.

Volltext

Combination strategies in myelodysplastic syndromes von Ornstein, Moshe C., Sekeres, Mikkael A.

Volltext

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) von Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, McDermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey A, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J, Braun, David, Einstein, David, Catalano, Paul J, Hammers, Hans

Volltext

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma von Tzeng, Alice, Diaz-Montero, C. Marcela, Rayman, Patricia A., Kim, Jin S., Pavicic, Paul G., Finke, James H., Barata, Pedro C., Lamenza, Marcelo, Devonshire, Sarah, Schach, Kim, Emamekhoo, Hamid, Ernstoff, Marc S., Hoimes, Christopher J., Rini, Brian I., Garcia, Jorge A., Gilligan, Timothy D., Ornstein, Moshe C., Grivas, Petros

Volltext